|1.||Shapiro, A: 3 articles (11/2011 - 09/2003)|
|2.||Gill, J C: 3 articles (11/2011 - 01/2004)|
|3.||Berntorp, E: 3 articles (11/2008 - 09/2003)|
|4.||Ewenstein, B M: 3 articles (08/2008 - 11/2003)|
|5.||Takamatsu, J: 3 articles (08/2006 - 07/2000)|
|6.||Fukutake, K: 3 articles (08/2006 - 07/2000)|
|7.||Yoshioka, A: 3 articles (08/2006 - 07/2000)|
|8.||Shirahata, A: 3 articles (08/2006 - 07/2000)|
|9.||Schwartz, B A: 3 articles (01/2004 - 02/2002)|
|10.||Scharrer, I: 3 articles (03/2002 - 06/2000)|
|1.||Hemophilia A (Haemophilia)
11/01/2009 - "Although KOGENATE and Kogenate FS/Bayer are nearly identical products, subtle manufacturing improvements to address the need for greater margins of safety from a pathogen transmission perspective have also led to a potentially improved immunogenicity profile (15% in previously untreated/minimally treated patients with severe hemophilia A for Kogenate FS/Bayer). "
03/01/2002 - "The study objectives were to assess the efficacy of KOGENATE Bayer (Kogenate FS) in achieving haemostasis during surgical procedures in patients with severe haemophilia A and to evaluate its safety when given in the doses needed for this purpose. "
01/01/2010 - "Postmarketing surveillance study of KOGENATE Bayer with Bio-Set in patients with haemophilia A: evaluation of patients' satisfaction after switch to the new reconstitution system."
10/01/1972 - "Studies on the response of patients with classic hemophilia to transfusion with concentrates of antihemophilic factor. "
09/16/1967 - "[Studies on a circulating anticoagulant against antihemophilic factor in patients with hemophilia A]."
11/01/2005 - "Prophylaxis, or the regular scheduled administration of antihemophilic factor concentrate, is effective in preventing bleeding. "
11/01/2003 - "This study supports the safety and efficacy of Humate-P administered in doses calculated in VWF:RCo units for the treatment of urgent bleeding episodes in patients with VWD."
12/01/2003 - "Hemostasis was achieved with a single dose of Kogenate in 94.8% of the 951 bleeding episodes recorded in the study. "
11/01/2009 - "Overall, KOGENATE and Kogenate FS/Bayer have a long history of safety in a variety of clinical settings, including treatment of bleeding, surgical management, and prophylaxis therapy."
06/01/2005 - "The antihemophilic factor consumption was markedly reduced only in patients with frequent joint bleeding. "
|3.||von Willebrand Diseases (von Willebrand's Disease)
11/01/2011 - "Thrombelastograph platelet mapping in a patient with von Willebrand disease who was treated with Humate-P."
05/01/1990 - "Correction of prolonged bleeding time in von Willebrand's disease with Humate-P."
09/01/1988 - "Humate-P for treatment of von Willebrand disease."
02/01/1977 - "The plasma from swine with von Willebrand's disease late after infusion contained high levels of antihemophilic factor without other detectable activities of the complex. "
05/01/1969 - "Similar fractions of plasma prepared from the blood of patients with classic hemophilia, von Willebrand's disease, or a circulating anticoagulant directed against antihemophilic factor contained, on the average, somewhat less protein than normal plasma; whether this difference was significant is not yet known. "
|4.||Systemic Lupus Erythematosus (Libman-Sacks Disease)
|5.||Liver Diseases (Liver Disease)
|1.||Factor VIII (Coagulation Factor VIII)
|2.||von Willebrand Factor
|4.||von Willebrand factor drug combination factor VIII
|6.||sugar formulated recombinant FVIII
|7.||6-pyruvoyltetrahydropterin synthase (PTPS)
|8.||Factor VIIa (Activated Factor VII)
|9.||recombinant FVIIa (rFVIIa)
|10.||human F8 protein
|1.||Tooth Extraction (Tooth Extractions)
|5.||Drug Therapy (Chemotherapy)